{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:46:41Z","timestamp":1778154401460,"version":"3.51.4"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"981","license":[{"start":{"date-parts":[[2007,6,29]],"date-time":"2007-06-29T00:00:00Z","timestamp":1183075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Overactive bladder (OAB) syndrome is the term used to describe the symptom complex of urinary urgency with or without urge incontinence, usually with frequency and nocturia. Drug treatment continues to have an important role in the management of women with OAB. Other treatment options include conservative management with lifestyle interventions, modification of fluid intake, and physiotherapy including bladder retraining. Surgery remains the last resort in the treatment and is usually reserved for intractable detrusor overactivity, as it is associated with significant morbidity. This article reviews the management of the overactive bladder with specific focus on newer developments in the medical treatment of OAB in women.<\/jats:p>","DOI":"10.1136\/pgmj.2007.057232","type":"journal-article","created":{"date-parts":[[2007,7,9]],"date-time":"2007-07-09T15:53:55Z","timestamp":1183996435000},"page":"481-486","source":"Crossref","is-referenced-by-count":32,"title":["Management of overactive bladder syndrome"],"prefix":"10.1093","volume":"83","author":[{"given":"Sushma","family":"Srikrishna","sequence":"first","affiliation":[{"name":"Department of Urogynaecology, King's College Hospital , London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dudley","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Urogynaecology, King's College Hospital , London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Cardozo","sequence":"additional","affiliation":[{"name":"Department of Urogynaecology, King's College Hospital , London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Vella","sequence":"additional","affiliation":[{"name":"Department of Urogynaecology, King's College Hospital , London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,6,29]]},"reference":[{"key":"2023042013083993400_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"2023042013083993400_bib2","first-page":"S66","article-title":"Prevalence of overactive bladder in women: results from the NOBLE program","volume":"12","author":"Stewart","year":"2001","journal-title":"Int Urogynaecol J"},{"key":"2023042013083993400_bib3","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"issue":"6A","key":"2023042013083993400_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0090-4295(97)00595-5","article-title":"The overactive bladder: Pharmacologic basis of drug treatment","volume":"50","author":"Andersson","year":"1997","journal-title":"Urology"},{"key":"2023042013083993400_bib5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-198835040-00006","article-title":"Current concepts in the treatment of disorders of micturition","volume":"35","author":"Andersson","year":"1988","journal-title":"Drugs"},{"key":"2023042013083993400_bib6","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","article-title":"A medium-term analysis of the subjective efficency of treatment for women with detrusor instability and low bladder compliance","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"2023042013083993400_bib7","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","article-title":"A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"2023042013083993400_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/978-1-4471-3513-5_2","volume-title":"Urodynamics","author":"Abrams","year":"1983","edition":"1st ed"},{"key":"2023042013083993400_bib9","first-page":"53","article-title":"Micturition patterns in a healthy female population, studied with a frequency-volume chart","volume":"114","author":"Larsson","year":"1988","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"2023042013083993400_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-410X.1992.tb15450.x","article-title":"Agreement between clinical methods of measurment of urinary frequency and functional bladder capacity","volume":"9","author":"McCormack","year":"1992","journal-title":"Br J Urol"},{"key":"2023042013083993400_bib11","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/gps.712","article-title":"Psychotropics among the home dwelling elderly -increasing trends","volume":"17","author":"Linjakumpu","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"key":"2023042013083993400_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/0002-9378(66)90395-4","article-title":"Urgency incontinence in the female","volume":"94","author":"Jeffcoate","year":"1966","journal-title":"Am J Obstet Gynecol"},{"key":"2023042013083993400_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1464-410x.2000.00434.x","article-title":"Conservative treatment of urge urinary incontinence in women: a suystematic review of randomised clinical trials","volume":"85","author":"Berghams","year":"2000","journal-title":"BJU Int"},{"key":"2023042013083993400_bib14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0022-5347(01)65148-6","article-title":"Comparison of oxybutynin and it's active metabolite, N-desmethyl-oxybutynin, in the human detrusor and parotid gland","volume":"157","author":"Waldeck","year":"1997","journal-title":"J Urol"},{"key":"2023042013083993400_bib15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00498259209053145","article-title":"Measurement of oxybutynin and its N-desethyl meatbolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers","volume":"22","author":"Hughes","year":"1992","journal-title":"Xenobiotica"},{"key":"2023042013083993400_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0022-5347(17)47191-6","article-title":"Characterization of the muscarinic cholinoreceptors in the human detrusor","volume":"134","author":"Nilvebrant","year":"1985","journal-title":"J Urol"},{"key":"2023042013083993400_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-2999(86)90697-7","article-title":"Dicyclomine, benzhexol and oxybutynin distingush between subclasses of muscarinic binding sites","volume":"123","author":"Nilvebrant","year":"1986","journal-title":"Eur J Pharmacol"},{"key":"2023042013083993400_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","article-title":"Once daily controlled versus immeadiate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group","volume":"161","author":"Anderson","year":"1999","journal-title":"J Urol"},{"key":"2023042013083993400_bib19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0090-4295(99)00259-9","article-title":"Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group","volume":"54","author":"Gleason","year":"1999","journal-title":"Urology"},{"key":"2023042013083993400_bib20","volume-title":"Differential effects of the antimuscarinic agents toterodine tartarate ER and oxybutynin chloride ER on recent memory in older subjects","author":"Kay","year":"2006"},{"key":"2023042013083993400_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"key":"2023042013083993400_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1254\/fpj.94.145","article-title":"Effects of propiverine hydrochloride and its metabolites on isolated guinea pig urinary bladder","volume":"94","author":"Haruno","year":"1989","journal-title":"Folia Pharmacol Japon"},{"key":"2023042013083993400_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/00365599509180578","article-title":"Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence","volume":"29","author":"Mazur","year":"1995","journal-title":"Scand J Urol Nephrol"},{"key":"2023042013083993400_bib24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.sc.3100750","article-title":"Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia: a double-blind, placebo-controlled clinical trial","volume":"37","author":"Stoher","year":"1999","journal-title":"Spinal Cord"},{"key":"2023042013083993400_bib25","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1345\/aph.18427","article-title":"Tolterodine use for symptoms of overactive bladder","volume":"33","author":"Ruscin","year":"1999","journal-title":"Ann Pharmacother"},{"key":"2023042013083993400_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","article-title":"Tolterodine \u2013 a new bladder selective antimuscarinic agent","volume":"327","author":"Nilvebrant","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"2023042013083993400_bib27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0024-3205(97)00057-X","article-title":"Tolterodine \u2013 a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data","volume":"60","author":"Nilvebrant","year":"1997","journal-title":"Life Sci"},{"key":"2023042013083993400_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00192-002-1009-0","article-title":"A new once daily formulation of tolterodine provides superior efficacy an is well tolerated in women with overactive bladder","volume":"14","author":"Swift","year":"2003","journal-title":"Int J Pelvic Floor Dysfunct"},{"key":"2023042013083993400_bib29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder","volume":"57","author":"Van","year":"2001","journal-title":"Urology"},{"key":"2023042013083993400_bib30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomised, double blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2023042013083993400_bib31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"2023042013083993400_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1185\/030079902125000570","article-title":"Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET)","volume":"18","author":"Sussman","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"2023042013083993400_bib33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003495-199855060-00008","article-title":"Tolterodine","volume":"55","author":"Hills","year":"1998","journal-title":"Drugs"},{"key":"2023042013083993400_bib34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/BF02201987","article-title":"Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation","volume":"15","author":"Jonas","year":"1997","journal-title":"World J Urol"},{"key":"2023042013083993400_bib35","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0022-5347(05)68951-3","article-title":"Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity","volume":"161","author":"Millard","year":"1999","journal-title":"J Urol"},{"key":"2023042013083993400_bib36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1464-410x.1998.00501.x","article-title":"Efficacy and safety of tolterodine in patients with detrusor instability: a dose ranging study","volume":"81","author":"Rentzhog","year":"1998","journal-title":"Br J Urol"},{"key":"2023042013083993400_bib37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"Br J Urol"},{"key":"2023042013083993400_bib38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","article-title":"Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis","volume":"50","author":"Appell","year":"1997","journal-title":"Urology"},{"key":"2023042013083993400_bib39","first-page":"984","article-title":"Determination of bioavailability of the quaternary ammonium compound trospium chloride in man from urinary excretion data","volume":"36","author":"Schladitz-Keil","year":"1986","journal-title":"Arzneimittel Forsch\/Drug Res"},{"key":"2023042013083993400_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5414\/CPP38223","article-title":"Trospium chloride: an effective option for medical treatment of bladder overactivity","volume":"38","author":"Fusgen","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2023042013083993400_bib41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1464-410x.2000.00575.x","article-title":"Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial","volume":"85","author":"Cardozo","year":"2000","journal-title":"BJU Int"},{"key":"2023042013083993400_bib42","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","article-title":"Trospium choride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia","volume":"75","author":"Madersbacher","year":"1995","journal-title":"Br J Urol"},{"key":"2023042013083993400_bib43","first-page":"905PH006","volume-title":"Effects of YM905, oxybutynin and darifenacin on carbachol induced intracellular calcium mobilization by dispersed longitudinal smooth muscle cells of guinea pig colon","author":"Ikeda","year":"1998"},{"key":"2023042013083993400_bib44","first-page":"905PH005","volume-title":"Effects of YM905, tolterodine and oxybutynin on M3 receptor mediated cytosolic free Ca2+ mobilization in acutely dissociated cells of guinea pig urinary bladder smooth muscle and murine submandibular gland","author":"Ikeda","year":"1998"},{"key":"2023042013083993400_bib45","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomised, double blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"key":"2023042013083993400_bib46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","article-title":"Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo and tolterodine controlled phase II dose-finding study","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"2023042013083993400_bib47","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"2023042013083993400_bib48","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0024-3205(97)00047-7","article-title":"Discovery and development of selective M3 antagonists for clinical use","volume":"60","author":"Alabaster","year":"1997","journal-title":"Life Sci"},{"key":"2023042013083993400_bib49","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"key":"2023042013083993400_bib50","article-title":"Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of phase III studies","author":"Chapple","journal-title":"J Urol"},{"key":"2023042013083993400_bib51","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.urology.2004.01.041","article-title":"Use of botulinum toxin A for the treatment of refractory overactive bladder symtptoms: an initial experience","volume":"63","author":"Rapp","year":"2004","journal-title":"Urology"},{"key":"2023042013083993400_bib52","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.urology.2003.12.007","article-title":"Urodynamic evidence of effectiveness of botulinum A toxin injection in the treatment of detrusor overactivity refractory to anticholinergic agents","volume":"63","author":"Kuo","year":"2004","journal-title":"Urology"},{"key":"2023042013083993400_bib53","first-page":"351","article-title":"Successful use of bladder botulinum toxin injection to treat refractory overactive bladder","volume":"169","author":"Chancellor","year":"2003","journal-title":"J Urol"},{"key":"2023042013083993400_bib54","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","article-title":"Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics","volume":"176","author":"Schmid","year":"2006","journal-title":"J Urol"},{"key":"2023042013083993400_bib55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0090-4295(97)00591-8","article-title":"A myogenic basis for the overactive bladder","volume":"50","author":"Brading","year":"1997","journal-title":"Urol"},{"key":"2023042013083993400_bib56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000138768","article-title":"Experimental hyperreflexia: Effect of intravesical administration of various agents","volume":"42","author":"Levin","year":"1991","journal-title":"Pharmacology"},{"key":"2023042013083993400_bib57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000280289","article-title":"Effects of nifedipine in women with unstable bladders","volume":"34","author":"Rud","year":"1979","journal-title":"Urol Int"},{"key":"2023042013083993400_bib58","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000280321","article-title":"Spontaneous phasic activity of the detrusor: a cause of uninhibited contractions in unstable bladder","volume":"35","author":"Laval","year":"1980","journal-title":"Urol Int"},{"key":"2023042013083993400_bib59","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(81)90527-4","article-title":"Flunarizine: a once daily therapy for urinary incontinence","volume":"ii","author":"Palmer","year":"1981","journal-title":"Lancet"},{"key":"2023042013083993400_bib60","first-page":"899","article-title":"Experimental study on the action of diltiazem on detrusor muscle and clinical evaluation in patients with detrusor hyperactivity","volume":"39","author":"Faustini","year":"1989","journal-title":"Arzneimittel-Forsch\/Drugs Res"},{"key":"2023042013083993400_bib61","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.sc.3100750","article-title":"Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyper-reflexia: a double-blind, placebo-controlled clinical trial","volume":"37","author":"Stoher","year":"1999","journal-title":"Spinal Cord"},{"key":"2023042013083993400_bib62","first-page":"387","volume-title":"The pharmacological basis of therapeutics","author":"Baldessarini","year":"1985","edition":"7th ed"},{"key":"2023042013083993400_bib63","first-page":"229","article-title":"Double-blind study of Imipramine and placebo for incontinence due to bladder instability","volume":"15","author":"Castelden","year":"1986","journal-title":"Age Aging"},{"key":"2023042013083993400_bib64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-5347(17)60942-X","article-title":"Comparison of action of imipramine (tofranil) and propantheline (probanthine) on detrusor contraction","volume":"107","author":"Diokono","year":"1972","journal-title":"J Urol"},{"key":"2023042013083993400_bib65","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jnnp.46.9.854","article-title":"The use of desmopressin (DDVAP) for nocturia in women multiple sclerosis","volume":"46","author":"Hilton","year":"1983","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023042013083993400_bib66","first-page":"385","article-title":"Women take control; desmopressin \u2013 a drug for daytime urinary incontinence","volume":"21","author":"Robinson","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"2023042013083993400_bib67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<513::AID-NAU7>3.0.CO;2-G","article-title":"Caspaicin and neurogenic detrusor hyperreflexia: a double blind placebo-controlled study in 20 patients with spinal cord lesions","volume":"17","author":"de","year":"1998","journal-title":"Neurourol Urodyn"},{"key":"2023042013083993400_bib68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0090-4295(97)00595-5","article-title":"The overactive bladder: pharmacologic basis of drug treatment","volume":"50","author":"Andersson","year":"1997","journal-title":"Urology"},{"key":"2023042013083993400_bib69","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0773.1992.tb00466.x","article-title":"Clinical pharmacology of potassium channel openers","volume":"70","author":"Andersson","year":"1992","journal-title":"Pharmacol Toxicol"},{"key":"2023042013083993400_bib70","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1046\/j.1523-1755.2000.00923.x","article-title":"Potassium channel openers as potential theraputic weapons in ion channel disease","volume":"57","author":"Lawson","year":"2000","journal-title":"Kidney Int"},{"key":"2023042013083993400_bib71","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1476-5381.1991.tb12233.x","article-title":"Comparison of the effects of several potassium-channel openers on rat bladder and rat portal vein in vitro","volume":"102","author":"Edwards","year":"1991","journal-title":"Br J Pharmacol"},{"key":"2023042013083993400_bib72","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0022-5347(17)38087-4","article-title":"Effects of pinacidil on detrusor instability in men with outlet obstruction","volume":"146","author":"Hedlund","year":"1991","journal-title":"J Urol"},{"key":"2023042013083993400_bib73","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1152\/physrev.00038.2003","article-title":"Urinary bladder contraction and relaxation: physiology and pathophysiology","volume":"84","author":"Andersson","year":"2004","journal-title":"Physiol Rev"},{"key":"2023042013083993400_bib74","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.eururo.2006.01.037","article-title":"Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"2023042013083993400_bib75","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s00345-001-0237-0","article-title":"Alpha adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha adrenoceptors antagonists","volume":"19","author":"Andersson","year":"2002","journal-title":"World J Urol"},{"key":"2023042013083993400_bib76","first-page":"117","article-title":"Prazosin: a neglected cause of genuine stress incontinence","volume":"79","author":"Dwyer","year":"1992","journal-title":"Obstet Gynecol"},{"key":"2023042013083993400_bib77","first-page":"253","article-title":"Pharmacology of lower urinary tract smooth muscles and penile erectile tissues","volume":"45","author":"Andersson","year":"1993","journal-title":"Pharmacol Rev"},{"key":"2023042013083993400_bib78","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1471-0528.1984.tb04767.x","article-title":"Treatment of motor urge incontinence with clenbutorol and flavoxate hydrochloride","volume":"91","author":"Grunberger","year":"1984","journal-title":"Br J Obstet Gynaecol"},{"key":"2023042013083993400_bib79","first-page":"275","article-title":"The effect of beta adrenoceptor agonists on urinary incontinence in the elderly","volume":"91","author":"Castleden","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"2023042013083993400_bib80","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/00365598109179583","article-title":"Influence of atropine and isoprenaline on detrusor hyperactivity in children with neurogenic bladder","volume":"15","author":"Naglo","year":"1981","journal-title":"Scan J Urol Nephrol"},{"key":"2023042013083993400_bib81","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-5347(05)68047-0","article-title":"Autoradiographic localization of tachykinin and calcitonin gene related peptide receptors in adult urinary bladder","volume":"163","author":"Burcher","year":"2000","journal-title":"J Urol"},{"key":"2023042013083993400_bib82","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0022-5347(05)66405-1","article-title":"Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats","volume":"165","author":"Abdel-Gawad","year":"2001","journal-title":"J Urol"},{"key":"2023042013083993400_bib83","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0022-5347(05)68558-8","article-title":"Sacral nerve stimulation for treatment of refractory urinary re incontinence. Sacral Nerve Stimulation Study Group","volume":"162","author":"Schmidt","year":"1999","journal-title":"J Urol"},{"key":"2023042013083993400_bib84","first-page":"560","article-title":"Experience with clam cystoplasty. A review","volume":"33","author":"Mast","year":"1995","journal-title":"Paraplegia"},{"key":"2023042013083993400_bib85","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1464-410X.1990.tb14951.x","article-title":"The clam cystoplasty","volume":"66","author":"Bramble","year":"1990","journal-title":"Br J Urol"},{"key":"2023042013083993400_bib86","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1464-410X.1987.tb05034.x","article-title":"Clam entero-cystoplasty in the neuropathic bladder","volume":"60","author":"McRae","year":"1987","journal-title":"Br J Urol"},{"key":"2023042013083993400_bib87","first-page":"344","article-title":"Cranberry juice helps the problem of mucus production in enterouroplastics","volume":"8","author":"Rosenbaum","year":"1989","journal-title":"Neurourol and Urodyn"},{"key":"2023042013083993400_bib88","first-page":"56","article-title":"Problem of secondary malignancy after urinary diversion and enterocystoplasty","volume":"142","author":"Harzmann","year":"1992","journal-title":"Scand J Urol Nephrol"},{"key":"2023042013083993400_bib89","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1464-410X.1995.tb07667.x","article-title":"Bile acid dysfunction after clam enterocystoplasty","volume":"76","author":"Barrington","year":"1995","journal-title":"Br J Urol"},{"key":"2023042013083993400_bib90","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0022-5347(17)38985-1","article-title":"Bladder autoaugmentation: partial detrusor excision to augment the bladder without use of bowel","volume":"142","author":"Cartwright","year":"1989","journal-title":"J Urol"},{"key":"2023042013083993400_bib91","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0094-0143(05)70314-1","article-title":"Bladder autoaugmentation","volume":"23","author":"Snow","year":"1996","journal-title":"Urol Clin Nth Am"},{"key":"2023042013083993400_bib92","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0022-5347(17)32725-8","article-title":"Early clinical experience with adult bladder autoaugmentation","volume":"152","author":"Kennelly","year":"1994","journal-title":"J Urol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/83\/981\/481\/50023140\/postgradmedj-83-481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/83\/981\/481\/50023140\/postgradmedj-83-481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T16:21:06Z","timestamp":1682007666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/83\/981\/481\/7045396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,29]]},"references-count":92,"journal-issue":{"issue":"981","published-online":{"date-parts":[[2007,6,29]]},"published-print":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2007.057232","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,7]]},"published":{"date-parts":[[2007,6,29]]}}}